137 related articles for article (PubMed ID: 33942735)
1. Changes in prolactin receptor location in prostate tumors.
López Fontana G; Rey L; Santiano F; López Fontana R; López Laur JD; Zyla L; Valdemoros P; Guerrero-Giménez ME; Fernández-Muñoz JM; Gómez S; Bruna F; Guglielmi JM; Carón R; López Fontana C
Arch Esp Urol; 2021 May; 74(4):419-426. PubMed ID: 33942735
[TBL] [Abstract][Full Text] [Related]
2. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
3. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Thomas LN; Merrimen J; Bell DG; Rendon R; Goffin V; Too CK
Prostate; 2014 May; 74(7):732-42. PubMed ID: 24615730
[TBL] [Abstract][Full Text] [Related]
4. Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation.
Perrot-Applanat M; Gualillo O; Buteau H; Edery M; Kelly PA
J Cell Sci; 1997 May; 110 ( Pt 9)():1123-32. PubMed ID: 9175708
[TBL] [Abstract][Full Text] [Related]
5. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
7. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N
FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024
[TBL] [Abstract][Full Text] [Related]
8. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T; Chi Y; Wang X; Xu C; Chen X; Liu Y; Huang S; Zhu X; Zhang H; Zhuo H; Wu D
Cell Death Dis; 2024 Feb; 15(2):128. PubMed ID: 38341429
[TBL] [Abstract][Full Text] [Related]
9. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
[TBL] [Abstract][Full Text] [Related]
10. Distribution of prolactin receptors suggests an intraductal role for prolactin in the mouse and human mammary gland, a finding supported by analysis of signaling in polarized monolayer cultures.
Ueda EK; Huang K; Nguyen V; Ferreira M; Andre S; Walker AM
Cell Tissue Res; 2011 Nov; 346(2):175-89. PubMed ID: 22081226
[TBL] [Abstract][Full Text] [Related]
11. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
López-Ozuna VM; Hachim IY; Hachim MY; Lebrun JJ; Ali S
Sci Rep; 2016 Aug; 6():30934. PubMed ID: 27480353
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
13. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
14. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.
Bole-Feysot C; Goffin V; Edery M; Binart N; Kelly PA
Endocr Rev; 1998 Jun; 19(3):225-68. PubMed ID: 9626554
[TBL] [Abstract][Full Text] [Related]
15. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
16. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of prolactin receptor (PRLR) in normal and tumorous adrenal tissues: separation of cellular endocrine compartments by laser capture microdissection (LCM).
Glasow A; Haidan A; Gillespie J; Kelly PA; Chrousos GP; Bornstein SR
Endocr Res; 1998; 24(3-4):857-62. PubMed ID: 9888587
[TBL] [Abstract][Full Text] [Related]
18. Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study.
Costa P; Catarino AL; Silva F; Sobrinho LG; Bugalho MJ
Endocr Pathol; 2006; 17(4):377-86. PubMed ID: 17525486
[TBL] [Abstract][Full Text] [Related]
19. Prolactin signaling influences the timing mechanism of the hair follicle: analysis of hair growth cycles in prolactin receptor knockout mice.
Craven AJ; Ormandy CJ; Robertson FG; Wilkins RJ; Kelly PA; Nixon AJ; Pearson AJ
Endocrinology; 2001 Jun; 142(6):2533-9. PubMed ID: 11356702
[TBL] [Abstract][Full Text] [Related]
20. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
